Literature DB >> 27672321

Lost in interpretation: should the highest VC value be used to calculate the FEV1/VC ratio?

Spyridon Fortis1.   

Abstract

Entities:  

Year:  2016        PMID: 27672321      PMCID: PMC5025010          DOI: 10.2147/COPD.S116214

Source DB:  PubMed          Journal:  Int J Chron Obstruct Pulmon Dis        ISSN: 1176-9106


× No keyword cloud information.
Dear editor Airflow obstruction or obstructive ventilatory defect (OVD) is defined as low forced expiratory volume in 1 second (FEV1) to vital capacity (VC) ratio. VC can be measured in various ways, and the definition of “low FEV1/VC” ratio varies. VC can be measured during forced expiration before bronchodilators (forced vital capacity [FVC]) and after bronchodilators (post-FVC), and during slow expiration (slow vital capacity [SVC]) and during inspiration (inspiratory vital capacity [IVC]). Theoretically, in a healthy person, VC values should be the same regardless of the maneuver used. Nevertheless, SVC is usually larger than FVC except in patients with no OVD and body mass index <25 kg/m2.1 In obstructive lung diseases, FVC may be reduced, which may result in an increase of FEV1/FVC ratio and misdiagnosis.2 For that reason, American Thoracic Society–European Respiratory Society recommends using SVC or IVC to calculate the FEV1/VC ratio.2 Approximately, 10% of smokers have FEV1% predicted <80% and FEV1/FVC >70%, a pattern known as preserved ratio impaired spirometry.3 Of all the subjects with FVC below the lower limit of normal (LLN) and FEV1/FVC > LLN, only 64% have restriction in lung volumes. The rest 36% have a nonspecific Pulmonary Function Test pattern.4 Approximately, 15% of patients with this nonspecific PFT pattern develop OVD in follow-up PFTs.4 It is possible that a portion of patients with obstructive lung disease remain underdiagnosed when FVC is used to compute FEV1/FVC ratio. Previous studies have shown that when the highest value of VC was used, the prevalence of COPD was significantly higher.1,5 Using a more sensitive test, like FEV1/SVC instead of FEV1/FVC, increases the prevalence of the disease. However, in the absence of true “gold standard” test, it may lead to overdiagnosis. The diagnostic test that can predict clinical outcomes better than the others is considered to be a better diagnostic test. Toren et al showed that if the largest VC is used to calculate the FEV1/VC, more patients with chronic bronchitis are diagnosed with OVD.5 On the other hand, individuals with no obstructive lung disease may be diagnosed with OVD. Another potential problem with using FEV1/SVC is that there are no available predicted values and LLNs for most populations. We should not compare the FEV1/SVC, FEV1/IVC, or FEV1/post-FVC with predicted values and LLNs derived from FEV1/FVC measurements. This approach has never been validated. Can the largest VC be used when the FEV1/VC <0.7 criterion is applied? This diagnostic criterion does not use predicted values. The answer again is “probably not”, as only the postbronchodilator FEV1/FVC <0.7 criterion has been validated. Although the postbronchodilator FEV1/FVC <0.7 is likely inferior to the FEV1/FVC < LLN criterion6,7 to diagnose OVD and confirm obstructive pulmonary disease, Global Initiative of Chronic Obstructive Lung Disease recommends its use as it is simple and has been used in numerous clinical trials.8 Thus, the only validated diagnostic criteria for OVD are the postbronchodilator FEV1/FVC <0.7 and the FEV1/VC < LLN, when LLN is available for this specific ratio. We should not diagnose OVD by using FEV1/SVC, FEV1/IVC, or FEV1/post-FVC when the predicted values and LLNs are derived from FEV1/FVC measurements. Dear editor We are grateful for the valuable comments by Dr Fortis about our recent paper about the importance of slow vital capacity (SVC).1,2 We seem to share the opinion that SVC is an overlooked aspect in spirometric diagnosing of chronic COPD. We also realized that we had missed a recent important paper by Fortis et al.3 There is a vast number of papers published debating on whether COPD should be diagnosed using the criterion forced expiratory volume in 1 second (FEV1)/vital capacity (VC) <0.7 or the criterion FEV1/VC below lower limit of normal (LLN).4,5 Our study was performed in a general population aged 50–64 years, an age interval where the difference between these two criteria seems to be of minor importance. This is also reflected in the similar prevalence of COPD regardless of whether the criterion FEV1/VC <0.7 or the criterion FEV1/VC below LLN was used (16.4% vs 15.6%). The main message from our paper was that use of only FVC will result in a considerable underdiagnosis of subjects with mild COPD.2 This is important as the use of SVC has been downplayed in recent international and national recommendations, despite the original international recommendations.4 In the age interval 50–64 years, we think that is the case regardless of the use of the criterion FEV1/VC <0.7 or the criterion FEV1/VC below LLN. We acknowledge Dr Fortis for the comment that we should use reference equations for SVC when applying the criterion FEV1/VC below LLN. However, reference equations are mostly obtained in population where subjects with asthma, COPD, and obstructive symptoms have been excluded, conditions that are associated with deviating SVC and FVC. Hence, we think that we can also use published reference equations as proxies for the criterion FEV1/VC below LLN.6 The increased prevalence of COPD when using the SVC concept may reflect an adequate diagnosis but may also reflect an overdiagnosis. Our results indicated, however, that the additional group of subjects added with the SVC concept was not respiratory healthy, as they had significantly increased prevalence of wheezing and higher residual volume, indicating air trapping. Whether this is of clinical relevance can only be elucidated in longitudinal studies. Dr Fortis indicated in his letter and in the cited article that there may exist an interaction between body mass index (BMI), COPD, and the difference between SVC and FVC.1,3 We have reanalyzed our material regarding the difference FVC–SVC according to BMI and LLNCOPDFVC (defined as FEV1/FVC ratio below LLN). The correlation coefficient (Spearman, rs) between FVC–SVC and BMI was 0.07 (P<0.05). Among those with LLNCOPDFVC, rs was 0.16 (P=0.11), and among those with no LLNCOPDFVC, rs was 0.06 (P<0.05). In Table 1, we have also outlined the difference FVC–SVC according to different BMI groups and LLNCOPDFVC.
Table 1

The difference between SVC and FVC (SVC–FVC, mL) according to different groups of BMI and LLNCOPDFVC (defined as FEV1/FVC below LLN)

BMI (kg/m2)Difference between SVC and FVC (SVC–FVC, mL)
NLLNCOPDFVCN=100Non-LLNCOPDFVCN=950AllN=1,050P-valuea
≤2533286 (24)51 (11)55 (10)ns
>25–30494137 (27)8 (11)86 (10)<0.05
>30224120 (43)9 (14)89 (13)<0.05

Notes: Standard error is given in parenthesis.

P-value for the difference between LLNCOPDFVC and non-LLNCOPDFVC.

Abbreviations: ns, not significant; BMI, body mass index; SVC, slow vital capacity; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; LLN, lower limit of normal.

Our analysis from a general population sample aged 50–64 years corroborates the results reported by Fortis et al, as SVC seems to be considerably larger than FVC among subjects with LLNCOPDFVC and BMI >25 kg/m2.1 Among subjects with BMI ≤25 kg/m2, there was no significant difference regarding SVC–FVC between those with or without COPD, but there was still a substantial difference between SVC and FVC. Hence, we think our results indicate that there are substantial differences between SVC and FVC, and this difference should not be disregarded in spirometric diagnosis of COPD.
  10 in total

1.  Lung function data interpretation.

Authors:  Martin R Miller
Journal:  Chest       Date:  2012-03       Impact factor: 9.410

2.  The difference between slow and forced vital capacity increases with increasing body mass index: a paradoxical difference in low and normal body mass indices.

Authors:  Spyridon Fortis; Edward O Corazalla; Qi Wang; Hyun J Kim
Journal:  Respir Care       Date:  2014-10-14       Impact factor: 2.258

3.  Interpretative strategies for lung function tests.

Authors:  R Pellegrino; G Viegi; V Brusasco; R O Crapo; F Burgos; R Casaburi; A Coates; C P M van der Grinten; P Gustafsson; J Hankinson; R Jensen; D C Johnson; N MacIntyre; R McKay; M R Miller; D Navajas; O F Pedersen; J Wanger
Journal:  Eur Respir J       Date:  2005-11       Impact factor: 16.671

4.  Clinical and radiographic predictors of GOLD-unclassified smokers in the COPDGene study.

Authors:  Emily S Wan; John E Hokanson; James R Murphy; Elizabeth A Regan; Barry J Make; David A Lynch; James D Crapo; Edwin K Silverman
Journal:  Am J Respir Crit Care Med       Date:  2011-04-14       Impact factor: 21.405

5.  A physiologically based model for spirometric reference equations in adults.

Authors:  Jonas Brisman; Jeong-Lim Kim; Anna-Carin Olin; Kjell Torén; Björn Bake
Journal:  Clin Physiol Funct Imaging       Date:  2014-10-15       Impact factor: 2.273

6.  Comment on: Wollmer P, Engström G. Fixed ratio or lower limit of normal (LLN) as cut-off value for FEV1/VC: An outcome study. Respiratory Medicine (2013) 107, 1460-1462.: Fixed ratio or lower limit of normal (LLN) as cut-off value for FEV1/VC.

Authors:  Carlos A Vaz Fragoso; Jeffrey J Pretto; Philip H Quanjer
Journal:  Respir Med       Date:  2015-05-02       Impact factor: 3.415

7.  Persistent Empiric COPD Diagnosis and Treatment After Pulmonary Function Test Showed No Obstruction.

Authors:  Spyridon Fortis; Edward O Corazalla; David R Jacobs; Hyun J Kim
Journal:  Respir Care       Date:  2016-05-10       Impact factor: 2.258

8.  The ratio of FEV1 to FVC as a basis for establishing chronic obstructive pulmonary disease.

Authors:  Carlos A Vaz Fragoso; John Concato; Gail McAvay; Peter H Van Ness; Carolyn L Rochester; H Klar Yaggi; Thomas M Gill
Journal:  Am J Respir Crit Care Med       Date:  2009-12-17       Impact factor: 21.405

9.  Vital capacity and COPD: the Swedish CArdioPulmonary bioImage Study (SCAPIS).

Authors:  Kjell Torén; Anna-Carin Olin; Anne Lindberg; Jenny Vikgren; Linus Schiöler; John Brandberg; Åse Johnsson; Gunnar Engström; H Lennart Persson; Magnus Sköld; Jan Hedner; Eva Lindberg; Andrei Malinovschi; Eeva Piitulainen; Per Wollmer; Annika Rosengren; Christer Janson; Anders Blomberg; Göran Bergström
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-05-02

10.  Lost in interpretation: should the highest VC value be used to calculate the FEV1/VC ratio?

Authors:  Spyridon Fortis
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-09-09
  10 in total
  3 in total

1.  Ratio of FEV1/Slow Vital Capacity of < 0.7 Is Associated With Clinical, Functional, and Radiologic Features of Obstructive Lung Disease in Smokers With Preserved Lung Function.

Authors:  Spyridon Fortis; Alejandro P Comellas; Surya P Bhatt; Eric A Hoffman; MeiLan K Han; Nirav R Bhakta; Robert Paine; Bonnie Ronish; Richard E Kanner; Mark Dransfield; Daniel Hoesterey; Russell G Buhr; R Graham Barr; Brett Dolezal; Victor E Ortega; M Bradley Drummond; Mehrdad Arjomandi; Robert J Kaner; Victor Kim; Jeffrey L Curtis; Russell P Bowler; Fernando Martinez; Wassim W Labaki; Christopher B Cooper; Wanda K O'Neal; Gerald Criner; Nadia N Hansel; Jerry A Krishnan; Prescott Woodruff; David Couper; Donald Tashkin; Igor Barjaktarevic
Journal:  Chest       Date:  2021-02-01       Impact factor: 10.262

2.  Predictive value of prebronchodilator and postbronchodilator spirometry for COPD features and outcomes.

Authors:  Spyridon Fortis; Michael Eberlein; Dimitris Georgopoulos; Alejandro P Comellas
Journal:  BMJ Open Respir Res       Date:  2017-12-18

3.  Lost in interpretation: should the highest VC value be used to calculate the FEV1/VC ratio?

Authors:  Spyridon Fortis
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-09-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.